Freenome, Inc. (FRNM)
| Market Cap | 1.34B +1,032.3% |
| Revenue (ttm) | 35.41M +1,128.7% |
| Net Income | -235.33M |
| EPS | -8.84 |
| Shares Out | 107.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 651,136 |
| Open | 12.64 |
| Previous Close | 12.86 |
| Day's Range | 11.59 - 12.71 |
| 52-Week Range | 9.95 - 17.50 |
| Beta | 0.45 |
| Analysts | Strong Buy |
| Price Target | 18.00 (+44.23%) |
| Earnings Date | Nov 10, 2026 |
About FRNM
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen™ CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The ... [Read more]
Financial Performance
In 2025, Freenome's revenue was $30.41 million, an increase of 955.14% compared to the previous year's $2.88 million. Losses were -$219.34 million, -22.02% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for FRNM stock is "Strong Buy." The 12-month stock price target is $18.0, which is an increase of 44.23% from the latest price.
News
Freenome rallies after launching lung cancer screening blood test
Freenome (FRNM) shares are moving higher after the company announced the launch of its SimpleScreen Lung, which enables eligible patients to be screened for both lung and colorectal cancer through…
Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option
– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw – – In an independent cohort, SimpleScreen Lung showed 85% sensitivity at ...
Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026
BRISBANE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the Company plans to r...
Freenome to present new data on updated version of SimpleScreen CRC
Freenome (FRNM) announced the company will present late-breaking data on an updated version of its SimpleScreen CRC blood-based screening test at the American College of Gastroenterology, ACG, 2026 An...
Elevance update guidelines cover Freenome CRC test, says Guggenheim
Guggenheim noted that Elevance Health’s (ELV) Carelon Healthcare Services unit updated its clinical guidelines for average-risk colorectal cancer screening to cover Guardant Health’s (GH) Shield and t...
Freenome initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Freenome (FRNM) with a Buy rating and $21 price target The shares are an opportunity to invest in a “scientifically robust company that has pursued a…
Freenome initiated with a Buy at Guggenheim
Guggenheim analyst Subbu Nambi initiated coverage of Freenome (FRNM) with a Buy rating and $21 price target
Freenome files to sell 75.19M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 75.19M shares of common stock. The company is not selling any…
Freenome Registration statement: Registration filing
Freenome filed a registration statement on August 18, 2026, providing details about a securities offering with the SEC.
Freenome initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Freenome (FRNM) with a Buy rating and $17 price target The firm says the company is known to investors given its first mover in liquid…
Freenome initiated with a Buy at BTIG
BTIG analyst Mark Massaro initiated coverage of Freenome (FRNM) with a Buy rating and $17 price target The firm views Freenome as a pioneer in blood-based testing and believes it…
Freenome granted Breakthrough Device Designation for SimpleScreen Lung
Freenome (FRNM) announced that the FDA has granted Breakthrough Device Designation to SimpleScreen Lung, the company’s investigational lung cancer screening test. The designation applies to the propos...
Freenome initiated with a Buy at Jefferies
Jefferies initiated coverage of Freenome (FRNM) with a Buy rating and $17 price target The company is developing a portfolio of blood-based cancer screening tests, the analyst tells investors in…
Freenome initiated with an Outperform at Leerink
Leerink initiated coverage of Freenome (FRNM) with an Outperform rating and $18 price target
FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen™ Lung Cancer Screening Test
BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the U.S. Food and Drug...
FDA approves Freenome's blood test for colorectal cancer screening
The U.S. FDA has approved Freenome's blood-based colorectal cancer screening test for older adults, paving the way for partner Abbott to launch it in the U.S. this fall, the companies said on Monday...
FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader acces...
Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection
– Freenome common stock expected to begin trading on the Nasdaq Capital Market under the ticker symbol "FRNM" on July 21, 2026 – – Gross proceeds to Freenome totaled more than $300 million through a P...